{
    "clinical_study": {
        "@rank": "40018", 
        "acronym": "OCA", 
        "arm_group": [
            {
                "arm_group_label": "Control without metformin", 
                "arm_group_type": "No Intervention", 
                "description": "conventional management of obesity including basic instructions on diet and physical activity"
            }, 
            {
                "arm_group_label": "Control with metformin", 
                "arm_group_type": "Experimental", 
                "description": "conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment"
            }, 
            {
                "arm_group_label": "Intervention with metformin", 
                "arm_group_type": "Experimental", 
                "description": "intensive physical activity course twice per week and monthly diet control by dietician plus Metformin treatment."
            }, 
            {
                "arm_group_label": "Intervention without metformin", 
                "arm_group_type": "No Intervention", 
                "description": "intensive physical activity course twice per week and monthly diet control by dietician"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesize that Metformin decreases weight, normalizes lipid profile and\n      increases insulin sensitivity; the study team hope to get better effect of weight decrease\n      and metabolic processes repair in the intensive treatment group with intervention of\n      physical activity, diet correction and Metformin use."
        }, 
        "brief_title": "Obesity in Children and Adolescents: Associated Risks and Early Intervention", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "During the first visit,  study participants would follow  the clinical investigation\n      (anthropometry, physical examination, blood tests (hormonal and biochemical state),\n      bioimpedance, ultrasound evaluation) and be attributed into 4 groups (matched for age,\n      gender, pubertal stage and BMI), 100 subjects in each group.\n\n        1. st group - control: during the first visit patients get standardized information on\n           healthy lifestyle, diet and exercise. Next visit (control) will be scheduled for the\n           clinical and laboratory evaluation after 12 months of intervention.\n\n        2. nd group - intensive diet and physical activity group: Children will be seen\n\n             1. by a dietician once a month for diet re-evaluation;\n\n             2. physical therapist, who will give physical activity course twice a week (1 h\n                each).\n\n             3. pediatric endocrinologist every 3 months. Clinical and laboratory evaluation after\n                12 months of intervention.\n\n        3. rd group - intensive diet and physical activity group plus insulin sensitization:\n           Metformin will be prescribed for this group of study children in the doses of 1000\n           mg/day Children will be seen by\n\n             1. a dietician once a month for diet re-evaluation;\n\n             2. physical therapist, who will give physical activity course twice a week (1 h\n                each);\n\n             3. pediatric endocrinologist every 3 month. Clinical and laboratory evaluation after\n                12 months of intervention.\n\n        4. th group- insulin sensitization without intensive diet and physical activity. Metformin\n           will be prescribed in the doses of 1000 mg/day after standardized information on\n           healthy lifestyle, diet and exercise during the first visit only. This group of\n           children will be seen by pediatric endocrinologist every 3 months.\n\n      Intervention duration - 12 months. In the case of metformin intolerance, children will\n      continue the study in 2nd group.\n\n      Clinical and laboratory evaluation after 12 months of intervention."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 10-17 yrs;\n\n          -  Weight > 85th percentile for age and gender (by IOTF);\n\n          -  Living in Kaunas and its region;\n\n          -  No obvious chronic diseases;\n\n          -  Not on steroid or other long-term treatment;\n\n          -  Informed consent of the patient and parents (official caregivers);\n\n        Exclusion Criteria:\n\n          -  Age less than 10 or above 17 yrs;\n\n          -  Diagnosis of type 1 diabetes;\n\n          -  Chronic illness that may affect physical activity and metabolic profile;\n\n          -  Insulin treatment;\n\n          -  Steroid treatment;\n\n          -  Planning to move from Kaunas or its region in the period of 1 year;\n\n          -  Protocol refused by the patient or his parents;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677923", 
            "org_study_id": "BE-2-1"
        }, 
        "intervention": {
            "arm_group_label": [
                "Control with metformin", 
                "Intervention with metformin"
            ], 
            "description": "Metformin 500 mg BID for 12 months", 
            "intervention_name": "Metformin", 
            "intervention_type": "Drug", 
            "other_name": "Metforal"
        }, 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "weight", 
            "body mass index", 
            "lipid profile", 
            "glucose profile"
        ], 
        "lastchanged_date": "September 25, 2013", 
        "location": {
            "contact": {
                "email": "rasa.verkauskiene@kaunoklinikos.lt", 
                "last_name": "Rasa Verkauskiene, Professor", 
                "phone": "00370-37-327097"
            }, 
            "facility": {
                "address": {
                    "city": "Kaunas", 
                    "country": "Lithuania", 
                    "state": "Eiveniu str. 2", 
                    "zip": "LT50009"
                }, 
                "name": "Rasa Verkauskiene"
            }, 
            "investigator": {
                "last_name": "Natalija Smetanina", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Lithuania"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase 3: Effect of Diet, Physical Activity and Insulin Sensitizer Metformin on Obesity and Associated Risks in Children and Adolescents.", 
        "other_outcome": {
            "description": "how many patients will have adverse events and withdraw the Metformin due to their intolerance or clinical / biochemical relapse", 
            "measure": "safety", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "rasa.verkauskiene@kaunoklinikos.lt", 
            "last_name": "Rasa Verkauskiene, Professor", 
            "phone": "00370-37-327097"
        }, 
        "overall_contact_backup": {
            "email": "natalija.smetanina@gmail.com", 
            "last_name": "Natalija Smetanina", 
            "phone": "00370-37-326801"
        }, 
        "overall_official": {
            "affiliation": "Lithuanian University of Health Sciences Hospital, Endocrinology Unit", 
            "last_name": "Rasa Verkauskiene, Professor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Lithuania: Bioethics Committee", 
                "Lithuania: State Medicine Control Agency - Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "decrease in body mass index", 
            "measure": "Body mass index changes", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677923"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lithuanian University of Health Sciences", 
            "investigator_full_name": "Rasa Verkauskiene", 
            "investigator_title": "Professor, Head of Endocrinology Unit and Institute in Lithuanian UHS", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Insulin sensitivity increase, homeostasis model assessment (HOMA-IR) decrease, insulin and glucose concentrations normalisation", 
                "measure": "Glucose homeostasis", 
                "safety_issue": "Yes", 
                "time_frame": "12 month"
            }, 
            {
                "description": "Lipid profile normalisation", 
                "measure": "Lipid profile", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Metabolic syndrome prevalence and risks decrease", 
                "measure": "Metabolic syndrome", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Hepatosteatosis prevalence decrease and liver function improvement, hepatic enzymes normalisation", 
                "measure": "Hepatosteatosis", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "PCOS clinical symptoms regression, menstrual cycle normalisation, hirsutism, androgens levels decreasing and estrogen, sex hormone-binding globulin (SHBG) levels increasing", 
                "measure": "Polycystic ovary syndrome (PCOS) and hyperandrogenism in females", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Lithuanian University of Health Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lithuanian University of Health Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}